

Paul S Aisen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3782531/publications.pdf>

Version: 2024-02-01

60
papers

21,333
citations

109264

35
h-index

128225

60
g-index

62
all docs

62
docs citations

62
times ranked

19670
citing authors

#	ARTICLE	IF	CITATIONS
1	Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging's Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2011, 7, 280-292.	0.4	5,550
2	Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. <i>Lancet Neurology</i> , The, 2013, 12, 207-216.	4.9	3,378
3	Clinical and Biomarker Changes in Dominantly Inherited Alzheimer's Disease. <i>New England Journal of Medicine</i> , 2012, 367, 795-804.	13.9	3,005
4	Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease. <i>New England Journal of Medicine</i> , 2014, 370, 311-321.	13.9	1,387
5	Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria. <i>Alzheimer's and Dementia</i> , 2016, 12, 292-323.	0.4	1,318
6	The A4 Study: Stopping AD Before Symptoms Begin?. <i>Science Translational Medicine</i> , 2014, 6, 228fs13.	5.8	588
7	The Preclinical Alzheimer Cognitive Composite. <i>JAMA Neurology</i> , 2014, 71, 961.	4.5	548
8	Randomized Trial of Verubecestat for Mild-to-Moderate Alzheimer's Disease. <i>New England Journal of Medicine</i> , 2018, 378, 1691-1703.	13.9	512
9	Testing the Right Target and Right Drug at the Right Stage. <i>Science Translational Medicine</i> , 2011, 3, 111cm33.	5.8	459
10	Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer's disease. <i>Brain</i> , 2010, 133, 3336-3348.	3.7	455
11	Randomized Trial of Verubecestat for Prodromal Alzheimer's Disease. <i>New England Journal of Medicine</i> , 2019, 380, 1408-1420.	13.9	397
12	Drug development in Alzheimer's disease: the path to 2025. <i>Alzheimer's Research and Therapy</i> , 2016, 8, 39.	3.0	323
13	On the path to 2025: understanding the Alzheimer's disease continuum. <i>Alzheimer's Research and Therapy</i> , 2017, 9, 60.	3.0	316
14	Association Between Elevated Brain Amyloid and Subsequent Cognitive Decline Among Cognitively Normal Persons. <i>JAMA - Journal of the American Medical Association</i> , 2017, 317, 2305.	3.8	311
15	Regional variability of imaging biomarkers in autosomal dominant Alzheimer's disease. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, E4502-9.	3.3	309
16	Mild cognitive impairment due to Alzheimer disease in the community. <i>Annals of Neurology</i> , 2013, 74, 199-208.	2.8	215
17	Association of Factors With Elevated Amyloid Burden in Clinically Normal Older Individuals. <i>JAMA Neurology</i> , 2020, 77, 735.	4.5	182
18	A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer's disease. <i>Nature Medicine</i> , 2021, 27, 1187-1196.	15.2	182

#	ARTICLE	IF	CITATIONS
19	Developing an international network for Alzheimer's™ research: the Dominantly Inherited Alzheimer Network. <i>Clinical Investigation</i> , 2012, 2, 975-984.	0.0	180
20	Tracking Early Decline in Cognitive Function in Older Individuals at Risk for Alzheimer Disease Dementia. <i>JAMA Neurology</i> , 2015, 72, 446.	4.5	142
21	Early and late change on the preclinical Alzheimer's cognitive composite in clinically normal older individuals with elevated amyloid β . <i>Alzheimer's and Dementia</i> , 2017, 13, 1004-1012.	0.4	139
22	A phase 3 trial of IV immunoglobulin for Alzheimer disease. <i>Neurology</i> , 2017, 88, 1768-1775.	1.5	136
23	Nilvadipine in mild to moderate Alzheimer disease: A randomised controlled trial. <i>PLoS Medicine</i> , 2018, 15, e1002660.	3.9	131
24	ADCS Prevention Instrument Project: The Mail-In Cognitive Function Screening Instrument (MCFSI). <i>Alzheimer Disease and Associated Disorders</i> , 2006, 20, S170-S178.	0.6	70
25	Targeted neurogenesis pathway-based gene analysis identifies ADORA2A associated with hippocampal volume in mild cognitive impairment and Alzheimer's disease. <i>Neurobiology of Aging</i> , 2017, 60, 92-103.	1.5	70
26	Neuroanatomical spread of amyloid β and tau in Alzheimer's™ disease: implications for primary prevention. <i>Brain Communications</i> , 2020, 2, fcaa007.	1.5	69
27	Disparities by Race and Ethnicity Among Adults Recruited for a Preclinical Alzheimer Disease Trial. <i>JAMA Network Open</i> , 2021, 4, e2114364.	2.8	68
28	The down syndrome biomarker initiative (DSBI) pilot: proof of concept for deep phenotyping of Alzheimer's™ disease biomarkers in down syndrome. <i>Frontiers in Behavioral Neuroscience</i> , 2015, 9, 239.	1.0	66
29	Cognitive Impairment Precedes and Predicts Functional Impairment in Mild Alzheimer's™ Disease. <i>Journal of Alzheimer's Disease</i> , 2015, 47, 205-214.	1.2	57
30	Detection of β -amyloid positivity in Alzheimer's™ Disease Neuroimaging Initiative participants with demographics, cognition, MRI and plasma biomarkers. <i>Brain Communications</i> , 2021, 3, fcab008.	1.5	51
31	Short-term Psychological Outcomes of Disclosing Amyloid Imaging Results to Research Participants Who Do Not Have Cognitive Impairment. <i>JAMA Neurology</i> , 2020, 77, 1504.	4.5	48
32	Vitamin E in aging persons with Down syndrome. <i>Neurology</i> , 2016, 86, 2071-2076.	1.5	47
33	Brain structure and function as mediators of the effects of amyloid on memory. <i>Neurology</i> , 2015, 84, 1136-1144.	1.5	44
34	Early-stage Alzheimer disease: getting trial-ready. <i>Nature Reviews Neurology</i> , 2022, 18, 389-399.	4.9	44
35	Accelerating rates of cognitive decline and imaging markers associated with β -amyloid pathology. <i>Neurology</i> , 2016, 86, 1887-1896.	1.5	42
36	Association Between Common Variants in <i>RBFox1</i> , an RNA-Binding Protein, and Brain Amyloidosis in Early and Preclinical Alzheimer Disease. <i>JAMA Neurology</i> , 2020, 77, 1288.	4.5	41

#	ARTICLE	IF	CITATIONS
37	Late-Life Depression Is Associated With Reduced Cortical Amyloid Burden: Findings From the Alzheimer's Disease Neuroimaging Initiative Depression Project. <i>Biological Psychiatry</i> , 2021, 89, 757-765.	0.7	41
38	Predicting the course of Alzheimer's progression. <i>Brain Informatics</i> , 2019, 6, 6.	1.8	40
39	The Utility of the Cognitive Function Instrument (CFI) to Detect Cognitive Decline in Non-Demented Older Adults. <i>Journal of Alzheimer's Disease</i> , 2017, 60, 427-437.	1.2	37
40	Randomized controlled trials in mild cognitive impairment. <i>Neurology</i> , 2017, 88, 1751-1758.	1.5	35
41	Alzheimer's Disease Clinical Trials: Moving Toward Successful Prevention. <i>CNS Drugs</i> , 2019, 33, 99-106.	2.7	33
42	Unsuccessful trials of therapies for Alzheimer's disease. <i>Lancet, The</i> , 2019, 393, 29.	6.3	31
43	Cognitive and functional changes associated with A β 2 pathology and the progression to mild cognitive impairment. <i>Neurobiology of Aging</i> , 2016, 48, 172-181.	1.5	28
44	Bayesian latent time joint mixed-effects model of progression in the Alzheimer's Disease Neuroimaging Initiative. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2018, 10, 657-668.	1.2	27
45	Statistical properties of continuous composite scales and implications for drug development. <i>Journal of Biopharmaceutical Statistics</i> , 2017, 27, 1104-1114.	0.4	23
46	Integration of bioinformatics and imaging informatics for identifying rare PSEN1 variants in Alzheimer's disease. <i>BMC Medical Genomics</i> , 2016, 9, 30.	0.7	20
47	Autosomal dominant and sporadic late onset Alzheimer's disease share a common <i>in vivo</i> pathophysiology. <i>Brain</i> , 2022, 145, 3594-3607.	3.7	20
48	Contribution of Alzheimer's biomarkers and risk factors to cognitive impairment and decline across the Alzheimer's disease continuum. <i>Alzheimer's and Dementia</i> , 2022, 18, 1370-1382.	0.4	17
49	AHEAD 3&45 study design: A global study to evaluate the efficacy and safety of treatment with BAN2401 for 216 weeks in preclinical Alzheimer's disease with intermediate amyloid (A3 trial) and elevated amyloid (A45 trial). <i>Alzheimer's and Dementia</i> , 2020, 16, e044511.	0.4	14
50	Associations among amyloid status, age, and longitudinal regional brain atrophy in cognitively unimpaired older adults. <i>Neurobiology of Aging</i> , 2019, 82, 110-119.	1.5	11
51	The relative efficiency of time-to-progression and continuous measures of cognition in presymptomatic Alzheimer's disease. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2019, 5, 308-318.	1.8	11
52	Automated and manual hippocampal segmentation techniques: Comparison of results, reproducibility and clinical applicability. <i>NeuroImage: Clinical</i> , 2019, 21, 101574.	1.4	11
53	The search for Alzheimer disease therapeutics " same targets, better trials?. <i>Nature Reviews Neurology</i> , 2020, 16, 597-598.	4.9	11
54	Predicting amyloid risk by machine learning algorithms based on the A4 screen data: Application to the Japanese Trial-Ready Cohort study. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2021, 7, e12135.	1.8	11

#	ARTICLE	IF	CITATIONS
55	Participant satisfaction with dementia prevention research: Results from Home-Based Assessment trial. <i>Alzheimer's and Dementia</i> , 2018, 14, 1397-1405.	0.4	10
56	A simulation study comparing slope model with mixed-model repeated measure to assess cognitive data in clinical trials of Alzheimer's disease. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2018, 4, 46-53.	1.8	9
57	A randomized clinical trial to evaluate home-based assessment of people over 75 years old. <i>Alzheimer's and Dementia</i> , 2019, 15, 615-624.	0.4	5
58	ATRI EDC: a novel cloud-native remote data capture system for large multicenter Alzheimer's disease and Alzheimer's disease-related dementias clinical trials. <i>JAMIA Open</i> , 2022, 5, ooab119.	1.0	4
59	F50403: TRCAD: Using Run-In Data for Screen Failure Reduction. <i>Alzheimer's and Dementia</i> , 2016, 12, P372.	0.4	1
60	Author response: A phase 3 trial of IV immunoglobulin for Alzheimer disease. <i>Neurology</i> , 2018, 90, 145-145.	1.5	1